I am interested in treatment-resistant depression and dementia. Clinically, I lead the Oxfordshire ECT and ketamine services and run a memory clinic.My main focus is developing policy and monitoring arrangements for rapidly acting antidepressants such as ketamine. I led the international academic conference on Ketamine and Related Compounds for Psychiatric Disorders in March 2018. I work on ways of optimizing the effects of ketamine and am local PI for trials of rapidly acting antidepressants.
Following an NIHR-funded case series exploring the use of repeated ketamine for resistant depression, we have now treated over 200 patients and are continuing to refine treatment protocols. I led a qualitative study of ECT, which led to the creation of a Healthtalk module of patients talking about their experience and an exploration of why experiences are so polarised.As Coordinating Editor of the Cochrane Dementia and Cognitive Improvement Group, I have led programmes on reviews of diagnostic test accuracy, and modifiable risk factors for dementia. I am currently exploring the use of telematics to help older people decide if they are still safe to drive. I support NIHR funded and commercial dementia trials as local PI.